# Guardant Health, Inc. Common Stock (GH) — Stock CV

Guardant Health, Inc. is a $22.5B healthcare company. Revenue grew 42.7% over the last year, and it currently loses money.

> Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening.

## Identity

- **Ticker**: GH
- **Sector**: Healthcare
- **Industry**: Services-Medical Laboratories
- **Headquarters**: PALO ALTO, CA
- **Employees**: 2 506
- **Website**: https://www.guardanthealth.com
- **Market cap**: $22.5B
- **Last price**: $167.40
- **Financial profile**: Solid

## Vitals (TTM)

- **Revenue**: $1.18B
- **Net income**: -$453M
- **Free cash flow**: -$241M
- **Revenue growth (YoY)**: 42.7%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 25 |
| Growth | 25 |
| Profitability | 0 |
| Health | 50 |
| Quality | 40 |
| Moat | 0 |

## Qualifications (beginner checklist) — 5 of 9 passed

- [x] Revenue growing — +42.7% YoY
- [ ] Profitable — -$453M TTM
- [x] Profit growing — +4.6% YoY
- [ ] Generates cash — -$241M TTM
- [x] Debt under control — current ratio 4.03
- [x] Established company — $22.5B market cap
- [ ] Not printing shares — +23.7% shares over ~5y
- [ ] Proven track record — 0/8 profitable years
- [x] Financially stable — Altman Z 4.5 — safe

## Experience (career milestones)

- **2022** — Guardant Health enrolled the first patient in the Screening for High-Frequency Malignant Disease (SHIELD)…
- **2021** — Guardant Health introduced Guardant Reveal, the first blood-only liquid biopsy test for the detection of…
- **2019** — Guardant Health launched the early-stage cancer assay called Lunar for academic and biopharmaceutical research in 2019
- **2018** — The company's U.S. initial public offering in 2018 raised $237.5 million, valuing Guardant Health at $3.3 billion
- **2018** — The joint venture, called Guardant Health AMEA, launched in 2018 and was purchased by Guardant Health for…
- **2017** — The GuardantOMNI test launched in 2017 and has been used for biopharmaceutical research

## Strengths

- High gross margin (65.0%)
- Revenue growing 42.7% year over year
- Altman Z-Score 4.47 — low bankruptcy-risk zone

## Watch-outs

- Not profitable — 38.3% net margin
- Negative free cash flow (-$240.7M)
- Thin interest coverage (-151.0×)
- Loss-making in 8 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $374M | -$406M | -$284M |
| FY2022 | $450M | -$655M | -$387M |
| FY2023 | $564M | -$479M | -$345M |
| FY2024 | $739M | -$436M | -$275M |
| FY2025 | $982M | -$416M | -$233M |

---

Source: https://stockcv.com/GH — derived from company filings; may be delayed or incomplete. Information, not investment advice.